LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF

Lakefront Biotherapeutics NV

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026

$29.79−0.11 (-0.37%)

Close on Oct 19, 2026

Lakefront Biotherapeutics NV income statement

Annual QuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	1,112	276	240	241	234	478	835	279	127	130	40
Cost of Revenue	30	35	–	12	1.63	–	–	–	–	–	–
Gross Profit	1,083	241	–	229	233	–	–	–	–	–	–
Research & Development	459	335	241	270	321	524	420	316	219	140	130
Selling & Marketing	6.10	17	5.68	3.48	3.78	66	25	4.15	2.80	1.79	1.18
Operating Expenses	–	–	–	–	–	709	517	355	246	163	150
Operating Income	295	-188	-88	-131	-172	-179	369	-47	-90	-11	-89
Interest Expense	1.03	0.91	1.77	6.88	12	9.39	1.27	0.78	0.94	0.05	0.05
Asset Impairment Charges	–	–	–	–	–	–	–	–	0	–	–
Pretax Income	301	-3.09	5.63	-71	-119	-310	149	-31	-116	54	-120
Income Tax Expense	-19	-1.80	9.61	0.57	1.39	1.23	-0.17	0.82	0.20	0.24	-1.22
Income from Continuing Operations	319	-1.28	-3.99	-71	-121	-311	149	-32	–	–	–
Income from Discontinued Operations	1.39	75	216	-147	18	5.57	1.16	2.98	–	–	–
Net Income incl. Noncontrolling Interests	321	74	212	-218	-103	-305	150	-29	-116	54	-118
Net Income	321	74	212	-218	-103	-305	150	-29	-116	54	-118
Net Income to Common	321	74	212	-218	-103	-305	150	-29	-116	54	-118
EPS (Basic)(per share)	4.87	1.12	3.21	-3.32	-1.58	-4.69	2.60	-0.56	-2.34	1.18	-3.32
EPS (Diluted)(per share)	4.87	1.12	3.21	-3.32	-1.58	-4.69	2.49	-0.56	-2.34	1.14	-3.32
Shares Outstanding (Basic, Weighted)(shares)	66	66	66	66	66	65	58	0.05	49	46	36
Shares Outstanding (Diluted, Weighted)(shares)	66	66	66	66	66	65	58	52	49	47	36
EBITDA	–	–	–	–	–	-160	381	-42	-86	-7.31	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 97.3%
Operating margin: 26.5%
Net margin: 28.9%
Return on equity, FY2025: –

Financial strength

Current ratio: 20.15
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 57.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.